

In the matter of the Canadian Anti-Doping Program;

**And in the matter of an anti-doping rule violation by Édouard Wanadi asserted by the
Canadian Centre for Ethics in Sport;**

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (“CCES”) conducted an Out-of-Competition Sample collection on October 11, 2022, in London, Ontario.
2. Mr. Édouard Wanadi (“the Athlete”) was selected for Doping Control. The Sample provided by the Athlete returned an Adverse Analytical Finding (“AAF”) for GW501516 metabolites, a non-specified Prohibited Substance.
3. Following receipt of the CCES’ Notice of Charge asserting an anti-doping rule violation (“ADRV”) for the presence and Use of GW501516, the Athlete waived his right to a hearing, admitted the violation and accepted the proposed period of Ineligibility and all other applicable Consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada. The CCES also maintains and implements the Canadian Anti-Doping Program (“CADP”), including providing anti-doping services to national sport organizations and their members.
5. As Canada’s national anti-doping organization, the CCES is in compliance with the World Anti-Doping Code (Code) and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of and participates in the activities of U SPORTS. According to Rule 1.3 of the CADP, the CADP provisions apply to all members of, and participants in activities of sport organizations adopting it. The CADP was issued for adoption by Canadian sport organizations on October 26, 2020, to be operational on January 1, 2021. U SPORTS adopted the CADP on January 27, 2021. Therefore, as a participant in U SPORTS activities prior to the date that his Sample was collected on October 11, 2022, the Athlete is subject to the CADP.

Doping Control

7. On October 11, 2022, the CCES, conducted an Out of Competition Sample collection session in London, Ontario. Testing was conducted on U SPORTS athletes as part of the CCES’ domestic test distribution plan, all pursuant to the CADP.
8. The Athlete was notified that he had been selected for Doping Control and, together with the doping control officer (DCO) from the CCES, completed the Sample collection process. The Athlete’s Sample code number was 4622261.

9. On October 13, 2022, the Athlete's Sample was received by the World Anti-Doping Agency (WADA) accredited laboratory for analysis, the Centre Armand-Frappier Santé Biotechnologie ("INRS"), in Laval, QC.

Results Management

10. The AAF was reported by the INRS on November 4, 2022. The Certificate of Analysis indicated the Presence of GW501516 metabolites (sulfoxide and sulfone).
11. GW501516 is classified as a non-specified Prohibited Substance on the 2022 WADA Prohibited List.
12. The CCES commenced an initial review and Notification into the Athlete's adverse analytical finding and issued a notification of a potential ADRV on November 7, 2022.
13. Subsequently, on November 10, 2022, the CCES imposed a mandatory Provisional Suspension on the Athlete pursuant to CADP Rule 7.4.1.
14. On November 13, 2022, in response to the CCES' Notification letter, the Athlete requested the opening of his B-Sample. On December 2, 2022, the INRS reported, through a certificate of analysis, that the Athlete's B-Sample analysis confirmed the presence of GW501516 metabolites (sulfoxide and sulfone).
15. On December 9, 2022, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of a Prohibited Substance.
16. In accordance with CADP Rule 10.2.1.1, the standard sanction for an ADRV involving the presence and Use of a Prohibited Substance, is a four (4) year period of Ineligibility. The CCES proposed the standard four (4) year sanction within its Notice of Charge of December 9, 2022.
17. On January 18, 2023, the Athlete requested a hearing through the Sport Dispute Resolution Centre of Canada ("SDRCC") to contest both the violation and the sanction asserted by the CCES. Subsequently, the Athlete withdrew his request for a hearing and submitted a waiver of hearing form, on April 25, 2023.

Confirmation of Violation and Sanction

18. On April 25, 2023, in accordance with CADP Rule 8.4.1, the Athlete waived his right to a hearing thereby admitting the ADRV and accepting both the asserted violation and the proposed period of Ineligibility and all other applicable Consequences outlined within the December 9, 2022, Notice of Charge.
19. Therefore, the sanction for this violation is a four (4) year period of Ineligibility which commenced on November 10, 2022, (the date the Athlete was provisionally suspended) and concludes on November 9, 2026. Further, in accordance with CADP Rules 10.1 and 10.10, any competitive results obtained by the Athlete during the Sample collection session on October 11, 2022, and from date of Sample collection, must be Disqualified.
20. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 10th day of May 2023.



Kevin Bean
Executive Director, Sport Integrity
CCES